Venaxis (Castle Rock, Colorado), an in vitro diagnostic company focused on obtaining FDA clearance for its APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, reported positive top-line results from its pivotal U.S. study.